PF-04308515

PF‑04308515 is an orally administered small molecule drug developed by Pfizer as a glucocorticoid receptor agonist. It was investigated primarily for its anti-inflammatory properties and was studied in Phase 1 clinical trials for indications including rheumatoid arthritis and insulin resistance. The compound acts by activating the glucocorticoid receptor to exert anti-inflammatory effects. Development appears to have been discontinued after Phase 1 trials.[1][2][5]

Other names

1206876-95-0UNII-S04A90872WUNII-S-04A90872WUNII-S 04A90872WS04A90872WS-04A90872WS 04A90872W2-Phenanthrenecarboxamide, 4b,5,6,7,8,8a,9,10-octahydro-6,7-dihydroxy-6-methyl-N-(2-methyl-3-pyridinyl)-10-oxo-7-phenyl-4b-(phenylmethyl)-, (4bR,6R,7R,8aS)(4bR,6R,7R,8aS)-4b-benzyl-6,7-dihydroxy-6-methyl-N-(2-methylpyridin‑3‑yl)-10‑oxo‑7‑phenyl‑4b,5 , 6 , 7 , 8 , 8 a ,9 ,10-octahydrophenanthrene‑2-carboxamide [3][5]